Skip to main content

Table 1 Patient characteristics in the ICIs-treated LUAD cohort

From: ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma

Variables

ANK2 mutation (n = 17)(%)

Wild type (n = 57)(%)

P

Age

  

0.028

  < 65

3 (17.6)

27 (47.4)

 

  ≥ 65

14 (82.4)

30 (52.6)

 

Sex

  

0.132

 Female

13 (76.5)

32 (56.1)

 

 Male

4 (23.5)

25 (43.9)

 

Smoking status

  

0.118

 Current/former

16 (94.1)

44 (77.2)

 

 Never

1 (5.9)

13 (22.8)

 
  1. Bold value indicates P < 0.05
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us